{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-134916","form_type":"8-K","ticker":"APLS","cik":"0001492422","company_name":"Apellis Pharmaceuticals, Inc.","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.213320+00:00","generated_at":"2026-05-15T08:09:01.101931+00:00","sec_items":["1.01","5.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Biogen to acquire Apellis for $41/share plus CVRs up to $4, total up to $45/share","bullets":["Biogen to pay $41.00 per share cash upfront plus one CVR per share for Apellis (APLS).","CVRs entitle holders to up to $4.00/share based on SYFOVRE net sales milestones ($1.5B or $2B).","Tender offer to commence for all shares; no stockholder vote required; minimum condition >50% tendered.","Support stockholders owning ~14% of shares agree to tender; termination fee $205M under certain conditions.","Apellis board unanimously recommends; deal expected to close by Sept 30, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-134916","json":"https://secwatch.observer/filing/0001193125-26-134916.json","markdown":"https://secwatch.observer/filing/0001193125-26-134916.md","text":"https://secwatch.observer/filing/0001193125-26-134916.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492422/000119312526134916/0001193125-26-134916-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492422/000119312526134916/d132653d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:09:01.101931+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"587f706803820beaca686c452ff1d1f146e33beb","claim":"Apellis Pharmaceuticals, Inc. entered into Agreement and Plan of Merger with Biogen Inc. (effective 2026-03-31).","evidence_excerpt":"On March 31, 2026, Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Biogen Inc., a Delaware corporation (“Parent”), and Aspen Purchaser Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Parent (“Purchaser”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312526134916/0001193125-26-134916-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Biogen Inc."},{"label":"Effective","value":"2026-03-31"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}